Tonghua Golden Horse Plans to Acquire Controlling Stake in Innovative Drugmaker Ba Jia Yi Through Wholly-Owned Subsidiary

证券时报··CN·Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Tonghua Golden Horse announced that its wholly-owned subsidiary, Guilin Golden Horse Innovation Investment, has signed a letter of intent for a merger and acquisition with Ba Jia Yi Pharmaceutical, aiming to acquire a controlling stake in Ba Jia Yi. Founded in 2011, Ba Jia Yi is an innovative pharmaceutical company focused on original new drug research and development. It holds 23 drug R&D patents and has clinical trial approvals for two Class 1 chemical new drug candidates and one Class 1 traditional Chinese medicine new drug candidate.

Impact on assets 1

Others▲ · 1 stocks

Off-coverage companies 2

八加一药业股份有限公司Private▲ Positive
Capitalrelevance

Target of acquisition, gaining resources and backing from Tonghua Golden Horse.

桂林金马创新投资有限公司Private± Mixed
relevance

© 2026 MarketIVNews